THRD•benzinga•
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Summary
Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% while reviewing strategic options.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga